Xgeva Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved understanding of bone metastasis management, advancement in rnk ligand inhibition research, increased cancer survival rates, expansion of oncology treatment protocols, availability of injectable biologics.

The growth in the forecast period can be attributed to increasing prevalence of metastatic cancers, rising demand for osteoporosis and bone health treatments, expansion of oncology supportive care services, growing adoption of biologic injectables, continued innovation in bone-targeted therapies. Major trends in the forecast period include increasing use of bone-targeted monoclonal antibodies, rising focus on skeletal-related event prevention, expansion of oncology supportive care therapies, growing adoption of injectable biologic treatments, enhanced emphasis on long-term bone health management.

The increasing prevalence of bone metastasis is driving growth in the Xgeva market. Bone metastasis occurs when cancer cells spread from their original site to the bones, leading to complications such as pain, fractures, and reduced mobility. This rise is linked to the growing global incidence of cancers, particularly breast, prostate, and lung cancers, which commonly metastasize to bones. As bone metastasis cases increase, the demand for effective treatments to manage skeletal complications grows, positioning Xgeva as a key therapy for preventing fractures and improving outcomes in patients with metastatic bone disease. For instance, according to Cancer Research UK, projections for 2038-2040 suggest approximately 510 new cases of bone sarcoma may be diagnosed annually in the UK. Therefore, the rising prevalence of bone metastasis is expected to propel the Xgeva market.

A key trend in the Xgeva market is expanding product offerings, improving formulations such as prefilled syringes, and enhancing patient access. Prefilled syringes are single-dose, ready-to-use devices preloaded with medication, simplifying administration, improving dosing accuracy, and increasing convenience for patients. For example, in March 2024, the Medicines and Healthcare Products Regulatory Agency (MHRA), a UK-based regulatory body, approved a high-concentration formulation of Amgen’s Xgeva (denosumab) as a 120 mg solution in a prefilled syringe under the International Recognition Procedure (IRP). This development streamlines treatment administration, reduces injection volume, and minimizes the risk of dosing errors, improving the patient experience.

In May 2024, Alvotech, a Luxembourg-based biosimilar developer, partnered with Dr. Reddy’s Laboratories SA to accelerate the commercialization of AVT03, a denosumab biosimilar to Xgeva. By leveraging Dr. Reddy’s established presence in the U.S., Europe, and the UK, the collaboration aims to increase access to affordable treatment options for patients with osteoporosis and cancer-related bone complications. Dr. Reddy’s Laboratories SA is an India-based global pharmaceutical company engaged in the development and manufacture of medicines.

Major companies operating in the xgeva market are Amgen Inc.

North America was the largest region in the xgeva market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the xgeva market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the xgeva market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the xgeva market by increasing costs of imported biologic production inputs, sterile syringes, injection devices, cold-chain logistics, and precision manufacturing equipment. Oncology treatment centers in North America and Europe are most affected due to reliance on globally sourced biologic components, while Asia-Pacific faces higher costs in import-dependent distribution channels. These tariffs contribute to increased therapy costs and pricing pressures in oncology care. However, they are also encouraging regional biologics manufacturing, local packaging operations, and supply chain diversification to support long-term treatment availability.

The xgeva market research report is one of a series of new reports that provides xgeva market statistics, including xgeva industry global market size, regional shares, competitors with a xgeva market share, detailed xgeva market segments, market trends and opportunities, and any further data you may need to thrive in the xgeva industry. This xgeva market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Xgeva (denosumab) is a monoclonal antibody used to prevent skeletal-related events (SREs) in patients with bone metastases from solid tumors and to treat giant cell tumors of bone and osteoporosis in high-risk patients. It is administered via subcutaneous injections by healthcare professionals.

The main formulations of Xgeva include 60 mg and 120 mg injections. The 60 mg dosage is typically given as a single injection tailored to patient-specific treatment regimens that require lower doses. The primary indications include bone metastases, giant cell tumor of bone (GCTB), and hypercalcemia of malignancy. It is used by hospitals, homecare, specialty clinics, and ambulatory surgical centers, and distributed through hospitals, retail pharmacies, and online pharmacies.

The xgeva market consists of sales of prefilled syringes and vials. Values in this market are ‘factory gate’ values, representing the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.